Navigation Links
Commentary and podcast on landmark gene therapy clinical trial for hemophilia B
Date:12/13/2011

New Rochelle, NY, December 12, 2011A recent article in the New England Journal of Medicine showed that Factor IX gene therapy in patients with hemophilia B was able to convert severe hemophilia to moderate or even mild disease. In a timely commentary, Thierry VandenDriessche, PhD, Methods Editor for Human Gene Therapy and Human Gene Therapy Methods says that this clinical trial represents an important milestone and "demonstrates unequivocally that gene therapy can result in a sustained therapeutic effect in hemophilia B patients." Read the commentary and listen to the accompanying podcast from Human Gene Therapy. Human Gene Therapy and HGT Methods are peer-reviewed journals published by Mary Ann Liebert, Inc..

The clinical trial reported in NEJM "builds on prior work and on encouraging pre-clinical data in non-human primates," states VandenDriessche and coauthor of the commentary with Marinee Chuah, PhD, Department of Gene Therapy & Regenerative Medicine, Free University of Brussels and the Center for Molecular and Vascular Biology, University of Leuven, Belgium. It demonstrated that injection of an adeno-associated virus (AAV) vector carrying the gene for the clotting factor FIX into patients with severe hemophilia B led to efficient delivery of the gene into liver cells and sufficient production of the FIX protein to transform the disease from severe to a moderate or mild form of hemophilia, although it does not represent a cure. This effect has been stable and has eliminated or substantially reduced the need for the patients to receive standard protein replacement, which is cumbersome and expensive. Substantial improvements in vector technology set the stage for this success; these included a self-complementary genome to increase efficiency pioneered by R. Jude Samulski, PhD, Director, Gene Therapy Center, University of North Carolina at Chapel Hill, and the use of a novel AAV capsid from a natural rhesus monkey isolate called AAV8, which was discovered and developed by James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy and Human Gene Therapy Methods, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Recently published articles in Human Gene Therapy document the development and optimization of the AAV vectors used to deliver the FIX gene in this clinical trial. Two key papers are:

"The successful treatment of patients with hemophilia B with gene therapy is a landmark event representing the culmination of over 20 years of work by many laboratories," says James M. Wilson, MD, PhD. "We are delighted that Human Gene Therapy was a venue for publishing critical aspects of the development of this product."


'/>"/>

Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2165
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. BUSM faculty author commentary on the global challenges of emerging viral infections
2. Expert commentary on Earth Days 40th anniversary
3. SectorWatch.biz Issues Commentary for Investors of Homeland Defense Companies FOUR, MAGS, NSSC, PNTR, BCO, and CKP
4. New American Chemical Society podcast: Genetically-engineered spider silk for gene therapy
5. American Migraine Foundation launches new podcast series
6. New American Chemical Society podcast: Tiny sea creature and a new medical adhesive
7. LSUHSC conducts landmark study of mid, long-term health effects of oil exposure
8. Landmark report reveals immense burden of osteoporotic fractures in Europe
9. OHSU Doernbecher Childrens Hospital conducts second phase of landmark Batten study
10. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
11. Fruit flies use horizontal landmarks for altitude control, says Caltech research team
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Commentary and podcast on landmark gene therapy clinical trial for hemophilia B
(Date:12/16/2016)... -- Research and Markets has announced the addition of ... 2021" report to their offering. ... The biometric vehicle access system market, in ... 14.06% from 2016 to 2021. The market is estimated to be ... Million by 2021. The growth of the biometric vehicle access system ...
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the addition ... offering. The report forecasts the global military biometrics market ... The report has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/12/2016)... -- Researchers at Trinity College, Dublin, are opening up ... material with Silly Putty. The mixture (known as "G-putty") ... sense pulse, blood pressure, respiration, and even the ... The research team,s findings were published Thursday in ... Due ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017   Pulmatrix, Inc . (NASDAQ: ... developing innovative inhaled therapies to address serious pulmonary diseases, ... infections in the lungs of CF patients, PUR1900, has ... by the U.S. Food & Drug Administration. ... to speed the development of novel drugs against important ...
(Date:1/17/2017)...  Only nine percent of U.S. consumers believe pharmaceutical ... 16 percent believe health insurance companies do, according to ... of U.S. adults believe health care providers (such as ... hospitals (23%). "We are in the midst ... , vice president of reputation management and public affairs ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Pono ... balanced, peaceful and healthy lifestyle, announced today the official launch of its much-anticipated Pono ... the mind. , In development for over a year, the patented Pono ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, ... recently announced a collaboration with the Heidelberg University Hospital and the German Cancer ... preparation, following the company’s successful launch of its CATS (Capture and Amplification ...
Breaking Biology Technology: